Applied Therapeutics Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Shoshana Shendelman

Chief Executive Officer (CEO)

US$2.7m

Compensación total

Porcentaje del salario del CEO	21.6%
Permanencia del CEO	8.3yrs
Participación del CEO	4.5%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	7.2yrs

Actualizaciones recientes de la dirección

Recent updates

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24

Applied Therapeutics EPS misses by $0.21

Nov 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Shoshana Shendelman en comparación con los beneficios de Applied Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$120m
Sep 30 2023	n/a	n/a	-US$97m
Jun 30 2023	n/a	n/a	-US$73m
Mar 31 2023	n/a	n/a	-US$70m
Dec 31 2022	US$3m	US$588k	-US$83m
Sep 30 2022	n/a	n/a	-US$95m
Jun 30 2022	n/a	n/a	-US$105m
Mar 31 2022	n/a	n/a	-US$105m
Dec 31 2021	US$2m	US$588k	-US$106m
Sep 30 2021	n/a	n/a	-US$102m
Jun 30 2021	n/a	n/a	-US$104m
Mar 31 2021	n/a	n/a	-US$106m
Dec 31 2020	US$5m	US$578k	-US$94m
Sep 30 2020	n/a	n/a	-US$88m
Jun 30 2020	n/a	n/a	-US$69m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$12m	US$550k	-US$46m
Sep 30 2019	n/a	n/a	-US$35m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$1m	US$500k	-US$17m

Compensación vs. Mercado: La compensación total ($USD2.72M) de Shoshana está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Shoshana ha aumentado mientras la empresa no es rentable.

CEO

Shoshana Shendelman (44 yo)

8.3yrs

Permanencia

US$2,722,293

Compensación

Dr. Shoshana Shendelman, PhD, has been Director of Applied Therapeutics Inc. since January 2016. Prior to founding Applied, she founded Clearpoint Strategy Group, a boutique life science consulting firm, w...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Shoshana Shendelman	Chair of the Board of Directors	no data	US$2.72m	4.53% $ 21.9m
Les Funtleyder	CFO, Principal Financial Officer & Independent Director	less than a year	US$79.55k	0.036% $ 173.1k
Riccardo Perfetti	Chief Medical Officer	5.7yrs	US$1.42m	0.13% $ 620.8k
Constantine Chinoporos	COO & Chief Business Officer	less than a year	sin datos	sin datos
Catherine Thorpe	Chief Accounting Officer	less than a year	sin datos	sin datos
Corwin Hooks	Chief Commercial Officer	no data	sin datos	sin datos

0.4yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de APLT no se considera experimentado ( 0.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shoshana Shendelman	Chair of the Board of Directors	8.3yrs	US$2.72m	4.53% $ 21.9m
Les Funtleyder	CFO, Principal Financial Officer & Independent Director	7.8yrs	US$79.55k	0.036% $ 173.1k
Joel Marcus	Independent Director	7.3yrs	US$87.16k	0.38% $ 1.9m
Jay Skyler	Independent Director	5yrs	US$93.85k	0% $ 0
Lawrence Steinman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Teena Lerner	Lead Independent Director	7.1yrs	US$99.35k	0.035% $ 171.0k
Stacy Kanter	Independent Director	4.9yrs	US$98.85k	0.042% $ 203.1k
Gregg Stone	Member of Scientific Advisory Board	no data	sin datos	sin datos
Donald Landry	Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Donald D'Amico	Member of Scientific Advisory Board	no data	sin datos	sin datos
Roy Freeman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Roxana Mehran	Member of Scientific Advisory Board	no data	sin datos	sin datos

7.2yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de APLT se considera experimentada (7.2 años de antigüedad promedio).

Applied Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Chair of the Board of Directors recently sold US$1.7m worth of stock

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Insufficient new directors

Recent updates

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold US$1.7m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Consensus EPS estimates fall by 36%

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

New major risk - Shareholder dilution

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

New major risk - Financial position

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$13.63

Price target decreased to US$28.80

Applied Therapeutics, Inc. Announces Executive Changes

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Price target increased to US$39.20

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Applied Therapeutics, Inc Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Price target decreased to US$34.40

Price target increased to US$49.40

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Chair of the Board of Directors recently bought US$145k worth of stock

Chief Medical Officer notifies of intention to sell stock

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Chief Medical Officer exercised options and sold US$714k worth of stock

Chief Medical Officer exercised options and sold US$97k worth of stock

Price target decreased to US$44.50

Applied Therapeutics Grants Fast Track Designation by FDA for AT-007 for Galactosemia

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

CFO & Head of Business Development recently sold US$108k worth of stock

Chief Commercial Officer recently sold US$53k worth of stock

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Independent Director exercised options to buy US$1.6m worth of stock.

New 90-day low: US$18.92

Chief Medical Officer exercised options and sold US$86k worth of stock

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Independent Director recently bought US$149k worth of stock

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $69 million.